Wednesday, 22 Jan 2020

PsA/SpA

Datesort ascending Type Title Save
11 Nov 2019 Social RT @DrPetryna: #ACR19 @rheumnow abs1913 Cohort study confirms the association of HLA-B*15 with peripheral joint involvement in AS but not i…
11 Nov 2019 Social RT @philipcrobinson: Nice data in r-axSpA treated with ixekizumab showing improvements in fatigue, pain and sleep #ACR19 @RheumNow Abs 1510…
11 Nov 2019 Social RT @EBRheum: Abst#1501 - 52w data for IXE in AxSpa, #ACR19 @RheumNow Take open label follow up with a grain of salt, but good to see pers…
11 Nov 2019 Social RT @DrPetryna: #ACR19 @rheumnow ABS1481 Corrona PsA/SpA Registy: real-world use of Apremilast +biologics happens mostly in pts who received…
11 Nov 2019 Social RT @DrPetryna: Do you feel comfortable combining apremilast with biologics in refractory/difficult to treat PsA patients ?
11 Nov 2019 ACR Video Gender Differences in Ankylosing Spondylitis: Dr. Torkell Juulsgaard
11 Nov 2019 Social RT @uptoTate: Small study suggests subclinical inflammation detected by MRI in joints of hand in PsA patients in MDA. Abst #1171 #ACR19 #AC…
11 Nov 2019 Social RT @synovialjoints: Does anti-TNF treatment halt radiographc progression in ankylosing spondylitis? #ACR19 @RheumNow Vote here
11 Nov 2019 Social RT @DrKanikaMonga: What a pleasant surprise to be included in the #axSpA poster tour today — my research - showing an association with wor…
10 Nov 2019 Social RT @DrKanikaMonga: Woo hoo! @rheum_cat and her poster on CV disease risk in aXSpA abstr #622 #ACR19 https://t.co/eaDyCKZs5J
07 Nov 2019 News Most Psoriatics Go on Biologics
05 Nov 2019 News Year in Review - Psoriatic Arthritis 2019
04 Nov 2019 Social Cancer Risk with psoriasis? Metanalysis of 58 studies shows that PSO is associated with an 18-22% increased risk of all cancers, highest w/ severe PSO. Increased risk of colon, laryngeal, liver, lymphoma/NHL, esophageal, oral cavity & pancreatic CA https://t.co/HYOej7mrbQ
04 Nov 2019 News EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis
01 Nov 2019 News Rinvoq (upadacitinib) Effective in Psoriatic Arthritis
01 Nov 2019 Social Data on 14 261 PsA patients (from 11 European registries) startin TNFi therapy - shows that half (56%) were in DAS28 remission and 53% were ACR20 responders after 6 months, and 3/4 were still on TNFi at 1 year https://t.co/RIHVjyJ7bn
01 Nov 2019 Social Study of 1810 AS pts from British registry on ankylosing spondylitis (BSRBR-AS) finds lower quality of life in AS is due to disease activity, depression, sleep disturbance, activity impairment, fibromyalgia, Widespread Pain, and tobacco smoking https://t.co/m0oG156CgY
31 Oct 2019 Social Claims analysis of psoriasis & PsA treated with inhibitors of TNF , IL-17 (SEC, IXE) or IL12/23 (UST) (2015-18) shows 2% of biologic starts had serious infections. SIE rates equal for TNFi & IL-17i; but were lower for IL-12/23 vs TNFi (HR=0.59; 0.39 -.90) https://t.co/YbNmEe19tS
31 Oct 2019 Social Swedish study of comorbidities compared 982 Psoriatic arthritis patients to the general population, finding PsA pts had higher rates of Obesity (BMI ≥ 30) (28.6% vs 16.3%), HTN (40.3% vs 24.1%) & diabetes (10.5% vs 6.2%). https://t.co/fFQ1almeJR
29 Oct 2019 Social Study of 238 PsA patients starting a biologic shows that comparing those w/ comorbid FM vs without, PsA pts with FM had lower biologic survival (50% vs 74%) and PsA-FM unlikely to achieve remission (3.4% at 3mos and 0% at 6 months). https://t.co/29RAIEtGZA